The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Potency of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluoro-2'-deoxyuridine against human melanoma in vitro and in vivo.
S. Schott
No relevant relationships to disclose
H. Niessner
No relevant relationships to disclose
T. Sinnberg
No relevant relationships to disclose
S. Venturelli
No relevant relationships to disclose
A. Berger
No relevant relationships to disclose
S. Noor
No relevant relationships to disclose
D. Mailaender-Sanchez
No relevant relationships to disclose
C. Garbe
No relevant relationships to disclose
C. Busch
No relevant relationships to disclose